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b Department of Haematology, University Medical Centre Utrecht, Utrecht, The NetherlandsThe study by Thomas and co-workers in this issue of EBioMedicine a well-characterized cohort of patients with acquired TTP (Thomas
provides detailed characteristics on the pathogenic properties of
antibodies that develop in patients with acquired thrombotic thrombo-
cytopenic purpura (TTP) (Thomas et al., 2015). It is now well-
established that TTP is due to dysregulation of primary hemostasis. A
crucial initial step in this process involves von Willebrand factor-
mediated adhesion of blood platelets to a damaged vessel wall. The
platelet-adhesive properties of VWF are dependent on its ability to
assemble into large polymers which are released from Weibel–Palade
bodies, unique storage organelles present in endothelial cells
(Valentijn et al., 2011). Upon their release, these polymers form extend-
ed parallel aligned strings that recruit platelets to sites of vascular
perturbation. The VWF cleaving protease ADAMTS13 controls VWF
multimer size by selectively cleaving a peptide bond in the A2 domain
of VWF that becomes exposed under the inﬂuence of ﬂuidic shear stress
(Crawley et al., 2011). In the absence of ADAMTS13 processing of VWF
polymers is incomplete, resulting in enhanced platelet adhesion at
sites of vascular injury (Fig. 1A).
For reasons that are so far poorly understood, autoantibodies direct-
ed against ADAMTS13 can develop in previously healthy individuals.
Like many other autoimmune disorders the highly polymorphic MHC
class II locus has been implicated in the pathogenesis of TTP. The
frequency of HLA-DR11 was signiﬁcantly increased in patients with
acquired TTP (Scully et al., 2010; Coppo et al., 2010). Feeding of antigen
presenting cells with ADAMTS13 revealed that a CUB2 domain derived
peptide is preferentially presented on HLA-DR11 (Sorvillo et al., 2013).
Based on this it was hypothesized that microbial peptides with
sequence overlap to this peptide may contribute to the onset of
acquired TTP (Verbij et al., 2014).While our knowledge on the underly-
ing cause for development of acquired TTP is still in its infancy, an in-
creasing number of studies have described the binding characteristics
of pathogenic antibodies in patients with acquired TTP (for review see
Verbij et al., 2014).
In the current study Thomas and co-workers take this approach a
step further by elegantly integrating functional and binding studies inDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.06.007.
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antibodies are present that are directed towards the spacer domain
(Fig. 1B). In a subset of patients antibodies directed towards the TSP2-
8 and CUB1-2 domain were identiﬁed. Antibodies exclusively targeting
the carboxy-terminal TSP2-8 and CUB1-2 domains were observed in 3
out of 92 patients analyzed. These results are in excellent agreement
with previous studies on the domain speciﬁcity of anti-ADAMTS13 anti-
bodies (Pos et al., 2011; Zheng et al., 2010). A major asset of the current
study is provided by combining mapping studies and linking these to
the inhibitory properties of IgG puriﬁed from patient plasma. Their
results show that inhibitory antibodies primarily target the spacer
domain of ADAMTS13. Unexpectedly, in about half of the patients only
weakly inhibitory antibodies were detected suggesting that functional
inhibition of ADAMTS13 alone cannot account for the severe deﬁciency
of ADAMTS13 in patients with acquired TTP.
Based on this observation the authors suggest that enhanced
antibody-mediated clearance provides a major pathogenic mechanism
in acquired TTP. This observation is corroborated by the reduced levels
of circulating ADAMTS13 antigen at ﬁrst presentation in patients with
non-inhibitory antibodies which appears to be a major determinant of
disease severity.
The current study strongly positions antibody-mediated clearance of
ADAMTS13 as an important pathogenic mechanism for acquired TTP.
Data included in this study show that residual levels of ADAMTS13
antigen at presentation are related to clinical outcome. Circulating
ADAMTS13-Ig complexes have been detected in plasma samples of
patients with acquired TTP (Ferrari et al., 2014). As yet our knowledge
on the size, composition and clearance-rate of ADAMTS13-Ig complexes
is insufﬁcient. Given their importance for the pathogenesis of acquired
TTP more detailed knowledge on the mechanism of clearance of
ADAMTS13-Ig complexes is urgently needed. This may help to further
improve current therapeutic approaches for treatment of patients
with acquired TTP.Disclosure
The authors declared no conﬂicts of interest.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Pathogenicity of anti-ADAMTS13 antibodies. (A) Release of platelet recruiting vonWillebrand factor polymers from endothelial cells. VWF polymers that are released fromWeibel–
Palade bodies assemble into ultra-large strings on the surface of endothelial cells. ADAMTS13 rapidly cleaves VWF strings thereby regulating adhesion of blood platelets. In the absence of
ADAMTS13 adhesion of bloodplatelets to persistingVWF stringsmaypromotemicrovascular thrombosis. Antibodies that develop inpatientswith acquired TTPmay inhibit the processing
activity of ADAMTS13 (indicated in red) or promote clearance of ADAMTS13 from the circulation (indicated in green). (B) Domain structure of ADAMTS13. Inhibitory antibodies that
develop in patients with acquired TTP are directed towards an antigenic determinant in the spacer domain (indicated in red). Low-afﬁnity non-inhibitory antibodies (indicated in
green) may potentially also target this site. Non-inhibitory antibodies (indicated in green) that promote the clearance of ADAMTS13 may also bind to the TSP2-8 and CUB domains.
The study by Thomas shows that clearance of ADAMTS13-Ig complexes contributes signiﬁcantly to the pathogenesis of acquired TTP.
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